Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. 2019

Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
Neurorehabilitation (NHNN), Neuroinflammation (IoN, UCL), Queen Square, London WC1N 3BG, United Kingdom.

OBJECTIVE Evaluate long-term efficacy and safety of ITB in treating MS-related spasticity over ∼ 20 years of service provision in a single centre. METHODS A single centre prospective observational cohort study was performed. Eligible subjects underwent ITB trial by bolus dose via lumbar puncture and responders proceeded to pump implantation. Demographics, spasticity scores (Ashworth), spasm score (Penn), stiffness, pain and discomfort (Visual Analogue Scale), mobility (10 M walk), spasticity treatment, and ITB doses were analysed longitudinally. RESULTS 106 people were included with 568 patient years of data. Ashworth, Penn and VAS/NRS mean scores improved post-trial compared with baseline (p < 0.001). Sustained efficacy was reported on Ashworth, Penn and VAS scores over time. After 1 year, 73 (69%) discontinued all oral antispasticity medications. Complication rates were low at 0.05 complications per pump year and mostly mechanical (usually catheter) related. In 8 ambulatory subjects, 7 (87%) continued to walk one year after pump insertion, 5 (62%) were still walking at time of analysis (mean follow up 3.4 years). CONCLUSIONS ITB is an effective and safe long term treatment for refractory MS related spasticity. Efficacy was sustained over time and the majority of subjects subsequently discontinued systemic medications. In a small cohort, ability to walk was preserved, indicating ITB should be considered earlier in this cohort.

UI MeSH Term Description Entries
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D009125 Muscle Relaxants, Central A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) Centrally Acting Muscle Relaxants,Central Muscle Relaxants,Relaxants, Central Muscle
D009128 Muscle Spasticity A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a "free interval") followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54) Clasp-Knife Spasticity,Spastic,Clasp Knife Spasticity,Spasticity, Clasp-Knife,Spasticity, Muscle
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
February 2006, Multiple sclerosis (Houndmills, Basingstoke, England),
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
January 2007, Acta neurochirurgica. Supplement,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
January 2003, Neurologia i neurochirurgia polska,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
February 2007, Journal of neurology,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
June 2005, Journal of neurology,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
January 2001, Topics in stroke rehabilitation,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
May 2011, Journal of rehabilitation medicine,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
January 1991, Clinical and experimental neurology,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
March 1994, The Medical letter on drugs and therapeutics,
Yezen Sammaraiee, and Martin Yardley, and Liz Keenan, and Katrina Buchanan, and Val Stevenson, and Rachel Farrell
November 1985, Lancet (London, England),
Copied contents to your clipboard!